Iovance Biotherapeutics (IOVA) Enterprise Value: 2010-2025
Historic Enterprise Value for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to $484.4 million.
- Iovance Biotherapeutics' Enterprise Value fell 81.96% to $484.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$500.4 million, marking a year-over-year decrease of 127.48%. This contributed to the annual value of $1.9 billion for FY2024, which is 7.27% up from last year.
- Per Iovance Biotherapeutics' latest filing, its Enterprise Value stood at $484.4 million for Q3 2025, which was up 77.33% from $273.2 million recorded in Q2 2025.
- Iovance Biotherapeutics' 5-year Enterprise Value high stood at $3.8 billion for Q1 2024, and its period low was $273.2 million during Q2 2025.
- In the last 3 years, Iovance Biotherapeutics' Enterprise Value had a median value of $1.3 billion in 2023 and averaged $1.5 billion.
- As far as peak fluctuations go, Iovance Biotherapeutics' Enterprise Value surged by 408.62% in 2024, and later tumbled by 86.45% in 2025.
- Iovance Biotherapeutics' Enterprise Value (Quarterly) stood at $1.8 billion in 2023, then climbed by 7.27% to $1.9 billion in 2024, then plummeted by 81.96% to $484.4 million in 2025.
- Its Enterprise Value was $484.4 million in Q3 2025, compared to $273.2 million in Q2 2025 and $732.1 million in Q1 2025.